Julia Alten

The MLL recombinome of acute leukemias in 2017

Claus Meyer, Thomas Burmeister, Daniela Gröger et al. · Leukemia · 2017 · 670 citations · Full text

The KMT2A recombinome of acute leukemias in 2023

Claus Meyer, Patrizia Larghero, Bruno A. Lopes et al. · Leukemia · 2023 · 192 citations · Full text

Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial

Peter Bader, Hermann Kreyenberg, Arend von Stackelberg et al. · Journal of Clinical Oncology · 2015 · 128 citations

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

Giovanni Cazzaniga, Paola De Lorenzo, Julia Alten et al. · Haematologica · 2017 · 89 citations · Full text

Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment

Cornelia Eckert, Nikola Hagedorn, Lucie Šrámková et al. · Leukemia · 2015 · 67 citations

Hematological Malignancy, Prognostic Evaluation, Pediatric Epidemiology +10